SCHEDULE: Armistice Capital Reports Vivos Therapeutics Stake

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting beneficial ownership of 4.99% of Vivos Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, indicating their beneficial ownership of Vivos Therapeutics, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially owned 729,755 shares, representing 4.99% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own these shares.
• The filing clarifies that the Master Fund disclaims beneficial ownership due to the investment management agreement.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting a change in beneficial ownership without significant new strategic or financial information.

Positives

• The filing provides transparency regarding significant beneficial ownership of Vivos Therapeutics, Inc. stock.
• The reporting persons hold a substantial stake, indicating confidence or strategic interest in the company.

Negatives

• The filing does not contain new financial performance data or strategic updates for Vivos Therapeutics, Inc.
• The Master Fund explicitly disclaims beneficial ownership, which could imply a lack of direct control despite shared dispositive power.

Risks

• Potential for future changes in beneficial ownership by Armistice Capital, LLC and Steven Boyd, which could impact share price.
• The filing does not provide insight into the specific investment strategy or intentions behind this ownership stake.

Future Outlook

No specific forward-looking statements or guidance related to Vivos Therapeutics, Inc. are present in this filing.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. This filing indicates Armistice Capital's significant, though not controlling, stake in Vivos Therapeutics, Inc., a company operating in the biotechnology or medical device sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant beneficial owner, potentially influencing market perception and trading activity.
• Management of Vivos Therapeutics, Inc.: Awareness of a substantial shareholder whose investment strategy could align with or diverge from management's plans.

Next Steps

• Armistice Capital, LLC and Steven Boyd will be responsible for the timely filing of any subsequent amendments to this Schedule 13G.

Key Dates

Keywords

Vivos Therapeutics, Armistice Capital, Schedule 13G, Beneficial Ownership, Investment Management, Steven Boyd, Common Stock